The Tecan-Fudan University Demo Lab opens in Shanghai
News Jun 24, 2013
The laboratory was opened in October 2012, at a ceremony attended by dignitaries, fellow scientists and colleagues from the Shanghai area. Equipped with an array of Tecan instruments, the laboratory serves as a technology hub for researchers and students in the department, and offers a perfect opportunity for potential Tecan customers in the Shanghai area to see Tecan systems in action.
The Demo Lab is extensively equipped with state-of-the-art instruments for researchers in drug discovery, including the innovative Freedom EVO® GenePaint™ solution for automating in situ hybridization, fluorescence in situ hybridization and immunohistochemistry technologies, Infinite® 200 PRO and Infinite M1000 PRO multimode microplate readers, and the HP D300 Digital Dispense.
Professor Yizhun Zhu, Dean of the School of Pharmacy at Fudan University, already has several Tecan instruments in his department, where the primary research focus is cardiovascular disease. He said: “The foundation of the Tecan-Fudan University Demo Lab reflects the excellent cooperation that has built up between universities and enterprise. The Demo Lab serves as a window for potential customers of Tecan instruments, where they can look in detail at how different assays and screening applications can be performed using this equipment. This is a perfect win-win situation, where Tecan’s reliable and high quality products and services will undoubtedly accelerate the development of scientific research in drug discovery within our school. We look forward to a successful partnership and expect to see many exciting developments as we work together in the future.”
David Martyr, CEO of Tecan Group, added: “The foundation of the Tecan-Fudan University Demo Lab gives both Tecan and the School of Pharmacy an excellent opportunity to learn from each other. We hope that our work together will accelerate drug discovery and result in the publication of many groundbreaking scientific papers. China is now one of Tecan’s most important markets, and we look forward to an extensive and long-term collaborative partnership with Fudan University.”
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
BioAscent Announces New CEO and Plans to Expand Discovery Services OfferingNews
BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018
EMBL Course: RNA Sequencing Library Preparation - How Low Can You Go?
Mar 19 - Mar 23, 2018
EMBL Course: Analysis and Integration of Transcriptome and Proteome Data
Mar 12 - Mar 16, 2018
EMBO | EMBL Symposium: Tissue Self-Organisation: Challenging the Systems
Mar 11 - Mar 14, 2018